CLINICAL_TRIALS
trial_result
· 2019-08-21
Clinical Trial Update: A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 dose-range finding study of ALX-0061 combination therapy in rheumatoid arthritis completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ablynx, a Sanofi company | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-08-21